Omalizumab as single-dose therapy for vernal keratoconjunctivitis

Vernal keratoconjunctivitis (VKC) is a bilateral inflammatory ocular condition often brought on by an allergic response. Patients with VKC commonly exhibit ocular symptoms such as photophobia, redness of the eyes, itching, discharge, and lacrimation, which can have profound effects on quality of life. The pathogenesis of the disease is both immunoglobulin E (IgE) and non-IgE mediated, invoking several hypersensitivity mechanisms. The treatment for VKC is mainly centered on symptom control with the use of antihistamines, calcineurin inhibitors, and corticosteroids. (Source: Annals of Allergy, Asthma and Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2xsoHMY